Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Anlotinib in Advanced NSCLC
NCT04544644Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2022
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04544644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544644.